Current Oncology, Vol. 30, Pages 5425-5447: HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

Current Oncology, Vol. 30, Pages 5425-5447: HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review

Current Oncology doi: 10.3390/curroncol30060411

Authors: Katarzyna J. Jerzak Nathaniel Bouganim Christine Brezden-Masley Scott Edwards Karen Gelmon Jan-Willem Henning John F. Hilton Sandeep Sehdev

The approval of CDK4/6 inhibitors has dramatically improved care for the treatment of HR+/HER2– advanced breast cancer, but navigating the rapidly-expanding treatment evidence base is challenging. In this narrative review, we provide best-practice recommendations for the first-line treatment of HR+/HER2– advanced breast cancer in Canada based on relevant literature, clinical guidelines, and our own clinical experience. Due to statistically significant improvements in overall survival and progression-free survival, ribociclib + aromatase inhibitor is our preferred first-line treatment for de novo advanced disease or relapse ≥12 months after completion of adjuvant endocrine therapy and ribociclib or abemaciclib + fulvestrant is our preferred first-line treatment for patients experiencing early relapse. Abemaciclib or palbociclib may be used when alternatives to ribociclib are needed, and endocrine therapy can be used alone in the case of contraindication to CDK4/6 inhibitors or limited life expectancy. Considerations for special populations—including frail and fit elderly patients, as well as those with visceral disease, brain metastases, and oligometastatic disease—are also explored. For monitoring, we recommend an approach across CDK4/6 inhibitors. For mutational testing, we recommend routinely performing ER/PR/HER2 testing to confirm the subtype of advanced disease at the time of progression and to consider ESR1 and PIK3CA testing for select patients. Where possible, engage a multidisciplinary care team to apply evidence in a patient-centric manner.